# GRAIL, Inc.

Summary updated: 2026-10-02T15:43:40.00753Z
Canonical: https://finbar.com/research/companies/grail-inc

## Overview

GRAIL, Inc. is a healthcare diagnostics company focused on early cancer detection. Its mission is to detect cancer early, when it can be cured, using a platform that combines genomic sequencing, clinical research, machine learning, software and automation. [1](https://app.finbar.com/go?id=P52233094)[2](https://app.finbar.com/go?id=P150172178) Its defining product is Galleri, a blood-based multi-cancer early detection test that looks for cancer-associated DNA signals and estimates where in the body they originated; it is intended to complement, not replace, recommended cancer screenings. [3](https://app.finbar.com/go?id=P47373049)[4](https://app.finbar.com/go?id=P150172182)

GRAIL’s commercial presence is centered in the United States, where Galleri launched in 2021; its UK activity includes the NHS-Galleri clinical trial. [4](https://app.finbar.com/go?id=P150172182)[5](https://grail.com/clinical-studies/nhs-galleri-trial-clinical/) Revenue was $147.2 million in fiscal 2025. [6](https://app.finbar.com/go?id=P150172231)
[1](https://app.finbar.com/go?id=P52233094)[2](https://app.finbar.com/go?id=P150172178)[3](https://app.finbar.com/go?id=P47373049)[4](https://app.finbar.com/go?id=P150172182)[6](https://app.finbar.com/go?id=P150172231)[5](https://grail.com/clinical-studies/nhs-galleri-trial-clinical/)

## Products & services

GRAIL’s principal commercial product is Galleri®, a prescription blood test intended to screen for a cancer signal in people without symptoms and to complement—not replace—recommended cancer screenings. It analyzes cell-free DNA fragments for cancer-associated methylation patterns, then predicts a likely tissue or organ source (the “Cancer Signal of Origin”) to help guide follow-up evaluation. Company materials describe it as screening for signals associated with more than 50 cancer types, including many without recommended screening tests. Galleri is available in the U.S. as a laboratory-developed test; as of the 2026 second-quarter report, it had not received FDA clearance or approval, and GRAIL had submitted a premarket approval application. [7](https://app.finbar.com/go?id=P150171831)[2](https://app.finbar.com/go?id=P150172178)[8](https://app.finbar.com/go?id=P150171835)[9](https://app.finbar.com/go?id=P150172192)

Galleri is ordered by a healthcare provider and requires a blood draw, which can be collected in physician offices, reference laboratories or mobile-phlebotomy settings; provider access also includes telemedicine. In PATHFINDER 2 initial results, GRAIL reported a 61.6% positive predictive value, 92% accuracy in predicting the cancer signal’s origin and a 0.4% false-positive rate. These are company-reported study results. [7](https://app.finbar.com/go?id=P150171831)[10](https://app.finbar.com/go?id=P95267908)[11](https://app.finbar.com/go?id=P4772799)

GRAIL also describes Diagnostic Aid for Cancer (DAC), a product in development intended to accelerate diagnostic resolution for people with clinical suspicion of cancer. The company reduced investment in DAC while prioritizing MCED and Galleri. Its financial reporting separately identifies development-services revenue but does not specify the services in detail. [12](https://app.finbar.com/go?id=P150172213)[13](https://app.finbar.com/go?id=T17187813)

For the six months ended June 30, 2026, screening revenue—reported as deriving from Galleri sales—was $82.474 million of $85.472 million in total revenue, or approximately 96.5%; for the second quarter, it was $42.642 million of $44.687 million, or approximately 95.4%. Development-services revenue was $2.998 million for the six-month period and $2.045 million for the quarter. [14](https://app.finbar.com/go?id=P150172206)[13](https://app.finbar.com/go?id=T17187813)
[7](https://app.finbar.com/go?id=P150171831)[2](https://app.finbar.com/go?id=P150172178)[8](https://app.finbar.com/go?id=P150171835)[9](https://app.finbar.com/go?id=P150172192)[10](https://app.finbar.com/go?id=P95267908)[11](https://app.finbar.com/go?id=P4772799)[12](https://app.finbar.com/go?id=P150172213)[13](https://app.finbar.com/go?id=T17187813)[14](https://app.finbar.com/go?id=P150172206)[13](https://app.finbar.com/go?id=T17187813)[13](https://app.finbar.com/go?id=T17187813)[13](https://app.finbar.com/go?id=T17187813)[13](https://app.finbar.com/go?id=T17187813)[13](https://app.finbar.com/go?id=T17187813)[13](https://app.finbar.com/go?id=T17187813)

## Geographic presence

GRAIL’s headquarters is in Sunnyvale, California, and its reported U.S. locations include Washington, D.C., and North Carolina; its U.S. clinical laboratory is in Research Triangle Park, North Carolina. The company also has a U.K. presence, including a London office. [15](https://grail.com/press-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test/)[16](https://grail.com/quality-and-regulatory/)[17](https://assets.grail.com/wp-content/uploads/2024/06/GRAIL-Corporate-Fact-Sheet-Version-1.pdf) Its 2025 annual report described a planned headquarters move from Menlo Park to Sunnyvale; the 2026 Q2 report documented the Sunnyvale premises becoming available for use in June 2026. [18](https://app.finbar.com/go?id=P98623029)[19](https://app.finbar.com/go?id=P150172077)

The company’s reported commercial screening revenue is primarily from the United States. For 2025, GRAIL reported $136.8 million in U.S. Galleri revenue and $147.2 million in total revenue, but did not provide a full geographic revenue breakdown. [14](https://app.finbar.com/go?id=P150172206)[20](https://grail.com/press-releases/grail-reports-fourth-quarter-and-full-year-2025-financial-results/) Its U.K. presence includes participation in an NHS clinical trial; this does not establish routine U.K. commercial sales. [21](https://app.finbar.com/go?id=P114508698)[22](https://app.finbar.com/go?id=P82751899) GRAIL reported approximately 910 employees at the end of 2025, with the majority based in the U.S.; it did not provide employee counts by country or location. [23](https://app.finbar.com/go?id=P15447873)
[18](https://app.finbar.com/go?id=P98623029)[19](https://app.finbar.com/go?id=P150172077)[14](https://app.finbar.com/go?id=P150172206)[21](https://app.finbar.com/go?id=P114508698)[22](https://app.finbar.com/go?id=P82751899)[23](https://app.finbar.com/go?id=P15447873)[15](https://grail.com/press-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test/)[16](https://grail.com/quality-and-regulatory/)[17](https://assets.grail.com/wp-content/uploads/2024/06/GRAIL-Corporate-Fact-Sheet-Version-1.pdf)[20](https://grail.com/press-releases/grail-reports-fourth-quarter-and-full-year-2025-financial-results/)

## Business segments

GRAIL reports one operating and reportable segment, rather than separate business segments. The segment encompasses its multi-cancer early-detection testing and services, including the Galleri blood test, along with related research and clinical-evidence development. [24](https://app.finbar.com/go?id=P150172155)[2](https://app.finbar.com/go?id=P150172178)[25](https://app.finbar.com/go?id=P150172198)

For revenue context—not as a reported segment breakdown—screening accounted for approximately 94% of FY2025 revenue, with development services contributing about 6%. In the six months ended June 30, 2026, screening represented approximately 96% of revenue and development services about 4%. These percentages are calculated from reported revenue categories; GRAIL does not report them as separate segments. [26](https://app.finbar.com/go?id=T5547671)[27](https://app.finbar.com/go?id=T17187843)
[24](https://app.finbar.com/go?id=P150172155)[2](https://app.finbar.com/go?id=P150172178)[25](https://app.finbar.com/go?id=P150172198)[26](https://app.finbar.com/go?id=T5547671)[26](https://app.finbar.com/go?id=T5547671)[26](https://app.finbar.com/go?id=T5547671)[27](https://app.finbar.com/go?id=T17187843)[27](https://app.finbar.com/go?id=T17187843)[27](https://app.finbar.com/go?id=T17187843)

## Company history

GRAIL was formed by Illumina in January 2016 to develop blood-based tests for early cancer detection, with Jeff Huber appointed as its founding CEO. The company raised more than $900 million in the initial close of its Series B financing in 2017. Hans Bishop became CEO in 2019. [28](https://grail.com/press-releases/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening/)[29](https://grail.com/press-releases/grail-hires-google-executive-jeff-huber-as-ceo-to-lead-development-for-early-cancer-detection/)[30](https://grail.com/press-releases/grail-closes-over-900-million-initial-investment-in-series-b-financing-to-develop-blood-tests-to-detect-cancer-early/)[31](https://grail.com/press-releases/grail-announces-appointment-of-hans-bishop-as-chief-executive-officer-and-strengthens-leadership-team-and-board-of-directors-with-new-appointments/)

In 2021, GRAIL introduced its Galleri multi-cancer early detection test in the United States and Illumina completed its acquisition of the company; Bob Ragusa became CEO that year. GRAIL became an independent, publicly traded company in June 2024, following Illumina’s distribution of most of its shares to Illumina stockholders. In 2026, the company submitted Galleri’s premarket approval application to the FDA. [32](https://grail.com/press-releases/grail-presents-interventional-pathfinder-study-data-at-2021-asco-annual-meeting-and-introduces-galleri-a-groundbreaking-multi-cancer-early-detection-blood-test/)[33](https://app.finbar.com/go?id=P19687737)[34](https://app.finbar.com/go?id=P113102700)[35](https://app.finbar.com/go?id=P104367767)[36](https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/)
[33](https://app.finbar.com/go?id=P19687737)[34](https://app.finbar.com/go?id=P113102700)[35](https://app.finbar.com/go?id=P104367767)[28](https://grail.com/press-releases/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening/)[29](https://grail.com/press-releases/grail-hires-google-executive-jeff-huber-as-ceo-to-lead-development-for-early-cancer-detection/)[30](https://grail.com/press-releases/grail-closes-over-900-million-initial-investment-in-series-b-financing-to-develop-blood-tests-to-detect-cancer-early/)[31](https://grail.com/press-releases/grail-announces-appointment-of-hans-bishop-as-chief-executive-officer-and-strengthens-leadership-team-and-board-of-directors-with-new-appointments/)[32](https://grail.com/press-releases/grail-presents-interventional-pathfinder-study-data-at-2021-asco-annual-meeting-and-introduces-galleri-a-groundbreaking-multi-cancer-early-detection-blood-test/)[36](https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/)

## Sources

1. [GRAIL, Inc. — Press release (2025 Y)](https://app.finbar.com/go?id=P52233094)
2. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172178)
3. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P47373049)
4. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172182)
5. [grail.com](https://grail.com/clinical-studies/nhs-galleri-trial-clinical/)
6. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172231)
7. [GRAIL, Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=P150171831)
8. [GRAIL, Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=P150171835)
9. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172192)
10. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P95267908)
11. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P4772799)
12. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172213)
13. [GRAIL, Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=T17187813)
14. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172206)
15. [grail.com](https://grail.com/press-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test/)
16. [grail.com](https://grail.com/quality-and-regulatory/)
17. [assets.grail.com](https://assets.grail.com/wp-content/uploads/2024/06/GRAIL-Corporate-Fact-Sheet-Version-1.pdf)
18. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P98623029)
19. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172077)
20. [grail.com](https://grail.com/press-releases/grail-reports-fourth-quarter-and-full-year-2025-financial-results/)
21. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P114508698)
22. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P82751899)
23. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P15447873)
24. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172155)
25. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P150172198)
26. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T5547671)
27. [GRAIL, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T17187843)
28. [grail.com](https://grail.com/press-releases/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening/)
29. [grail.com](https://grail.com/press-releases/grail-hires-google-executive-jeff-huber-as-ceo-to-lead-development-for-early-cancer-detection/)
30. [grail.com](https://grail.com/press-releases/grail-closes-over-900-million-initial-investment-in-series-b-financing-to-develop-blood-tests-to-detect-cancer-early/)
31. [grail.com](https://grail.com/press-releases/grail-announces-appointment-of-hans-bishop-as-chief-executive-officer-and-strengthens-leadership-team-and-board-of-directors-with-new-appointments/)
32. [grail.com](https://grail.com/press-releases/grail-presents-interventional-pathfinder-study-data-at-2021-asco-annual-meeting-and-introduces-galleri-a-groundbreaking-multi-cancer-early-detection-blood-test/)
33. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P19687737)
34. [GRAIL, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P113102700)
35. [GRAIL, Inc. — Full financial report (2024 Y)](https://app.finbar.com/go?id=P104367767)
36. [grail.com](https://grail.com/press-releases/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.